# Olezarsen bij matige hypertriglyceridemie: CV-uitkomstpotentieel

*geplaatst 2025-10-02 · Cholesterol · The New England journal of medicine · doi 10.1056/NEJMoa2507227 · https://hartvaat.nl/2025/10/02/olezarsen-bij-matige-hypertriglyceridemie-cv-uitkomstpotentieel/*

Studie onderzocht olezarsen (anti-APOC3 antisense) bij matige hypertriglyceridemie. Het middel verlaagde triglyceriden significant en de CV-uitkomsttrial moet het klinische voordeel bevestigen.

## English: Targeting APOC3 with Olezarsen in Moderate Hypertriglyceridemia.

This study of olezarsen targeting APOC3 in moderate hypertriglyceridemia demonstrated significant triglyceride reduction, addressing the unmet need for effective triglyceride-lowering therapy in the broader cardiovascular risk population.

## Abstract (original, from the publication)

BACKGROUND: Highly effective therapies to reduce triglyceride levels are lacking. Olezarsen is an N-acetylgalactosamine-conjugated antisense oligonucleotide that targets the messenger RNA of apolipoprotein C-III, which inhibits triglyceride clearance. METHODS: In this phase 3, international, double-blind, randomized, placebo-controlled trial, we enrolled patients with moderate hypertriglyceridemia (triglyceride level, 150 to 499 mg per deciliter) and elevated cardiovascular risk or with severe hypertriglyceridemia (triglyceride level, ≥500 mg per deciliter) and randomly assigned them in a 1:3 ratio to a 50-mg or 80-mg cohort. The patients were then randomly assigned in a 3:1 ratio to receive monthly subcutaneous olezarsen or matching placebo within each cohort. The primary outcome was the least-squares mean percent change in triglyceride level from baseline to 6 months among the patients with moderate hypertriglyceridemia, reported as the difference between each olezarsen dose group and the placebo group (the placebo-adjusted change). RESULTS: A total of 1349 patients (254 in the olezarsen 50-mg group, 766 in the olezarsen 80-mg group, and 329 in the placebo group) were included in the primary efficacy analysis. The median age was 64 years, 40% of the patients were women, and the median triglyceride level at baseline was 238.5 mg per deciliter (interquartile range, 190.5 to 307.5). At 6 months, the placebo-adjusted least-squares mean change in triglyceride level was -58.4 percentage points (95% confidence interval [CI], -65.1 to -51.7; P<0.001) in the olezarsen 50-mg group and -60.6 percentage points (95% CI, -67.1 to -54.0; P<0.001) in the olezarsen 80-mg group. The incidence of serious adverse events appeared to be similar across the trial groups. CONCLUSIONS: Among patients with moderate hypertriglyceridemia and elevated cardiovascular risk, treatment with olezarsen resulted in significantly greater reduction in triglyceride levels at 6 months than placebo. (Funded by Ionis Pharmaceuticals; ESSENCE-TIMI 73b ClinicalTrials.gov number, NCT05610280.).

Auteurs: Brian A Bergmark, Nicholas A Marston, Thomas A Prohaska, Veronica J Alexander, Andre Zimerman, Filipe A Moura, Yu Mi Kang, Julia Weinland, Sabina A Murphy, Erica L Goodrich, Shuanglu Zhang, Dan Li, Maciej Banach, Erik Stroes, Michael T Lu, Sotirios Tsimikas, Robert P Giugliano, Marc S Sabatine

---
Bron: The New England journal of medicine, https://doi.org/10.1056/NEJMoa2507227. Bijgewerkt 2026-07-03T13:30:53Z. Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies.